• Systems
  • Applications
  • Support
  • News & Events
    • News
    • Events
  • About Us
    • Who Is Celsee
    • Our Team
    • Our Board
    • Careers
  • Contact Us
    • Distributors
Celsee
  • Systems
  • Applications
  • Support
  • News & Events
    • News
    • Events
  • About Us
    • Who Is Celsee
    • Our Team
    • Our Board
    • Careers
  • Contact Us
    • Distributors

News

2018

Celsee Launches Genesis System to Overcome Prior Limits of Single-cell Analysis

Ann Arbor, Mich. – October 25, 2018 – Celsee, Inc., today launched its first product, the Genesis system, designed to overcome the limitations of… | 10/25/2018

Celsee, Inc. Enters into Supply Agreement with Argonaut Manufacturing Services

(February 14, 2018) Plymouth MI – Argonaut Manufacturing Services, a contract manufacturing organization (CMO) serving the life science and molecula… | 2/22/2018

Celsee and IncellDx Sing Co-commercialization Agreement Following Successful Lung Cancer/CTC PD-L1 Feasibility Study

Minimal expression of PD-L1 in standard-of-care methods that would have resulted in a negative call showed a positive expression using the combined ap… | 1/10/2018

2017

Zomedica Pharmaceuticals Corp. Enters Into License and Supply Agreement with Celsee, Inc. for Cancer Liquid Biopsy Platform

Targeting non-invasive veterinary cancer diagnostic assay ANN ARBOR, Mich., Dec. 21, 2017 (GLOBE NEWSWIRE) — Zomedica Pharmaceuticals Corp. (NYSE Am… | 12/21/2017

Celsee Diagnostics Awarded Additional Patents for their Innovative Microfluidic Technologies

Enrich rare circulating tumor cells from whole blood then isolate and retrieve a single cell. Celsee Diagnostics, an innovator in microfluidic rare-ce… | 9/15/2017

Celsee Diagnostics Adds another Patent to IP Portfolio Expanding Protection of the Celsee PREP400 Platform

The automated Celsee PREP400 is designed for hands-free CTC capture and characterization Celsee Diagnostics, an innovator in microfluidic rare-cell is… | 7/26/2017

Celsee Diagnostics Continues to Grow IP Portfolio, Adding Three More Patents to its Expanding Library

The automated Celsee PREP400 is designed for hands-free CTC capture and characterization Celsee Diagnostics, an innovator in microfluidic rare-cell is… | 5/16/2017

Celsee Diagnostics Demonstrates New Celsee™ PREP SingleCell™ Technology at AACR Annual Meeting 2017

Innovative platform streamlines rare single-cell enrichment, characterization and retrieval Celsee Diagnostics, an innovator of cutting-edge microflui… | 4/04/2017

Celsee Diagnostics Adds Industry Veteran John L. “Kip” Miller to its Board

Celsee Diagnostics, an innovator of cutting-edge rare and single cell detection products, announced the appointment of John L. “Kip” Miller to its… | 3/15/2017

Celsee Diagnostics, IncellDx Announce Immuno-Oncology Research Agreement

Collaborative studies will focus on the use of circulating tumor cells (CTCs) as a biospecimen for PD-L1 quantification and as a tool for tailoring th… | 2/14/2017

Celsee Diagnostics Announces ISO 13485:2003 Registration

International standard registration will facilitate access to new markets Celsee Diagnostics, an innovator of cutting-edge rare cell isolation and cha… | 2/08/2017

Zomedica Announces Research Agreement with Celsee Diagnostics for Cancer Liquid Biopsy

Zomedica Pharmaceuticals Corp, (TSX-V:ZOM), a veterinary pharmaceutical and health care solutions company, today announced it has entered into a resea… | 1/11/2017

 

2016

Celsee Diagnostics Receives Patent Issuance in China for Its Fundamental Microfluidic Cell Capture Technology

Microfluidic system allows for rare single-cell enrichment, analysis and retrieval. Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy pro… | 12/22/2016

Celsee Diagnostics Expands IP; Adding Another Patent for Single-Cell Capture and Retrieval Systems

Microfluidic system allows for rare single-cell enrichment, analysis and retrieval Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy prod… | 12/15/2016

Celsee Diagnostics Named PM360 Trailblazer Award Winner for Medical Device Company of the Year

Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, announced today that PM360, a leading trade magazine for marketing decision m… | 9/27/2016

Celsee Diagnostics Adds Another Patent to IP Portfolio

“System for Imaging Captured Cells” was assigned U.S. Patent No. 9404864 Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products a… | 8/03/2016

Celsee Diagnostics Adds Another Patent to IP Portfolio

Collaborative studies will determine the feasibility of using circulating tumor cells (CTCs) as a biospecimen for mutation analysis. Celsee Diagnostic… | 7/26/2016

Celsee Diagnostics selected as a 2016 Red Herring Top 100 North America winner

Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, announced today that the company has been selected as a 2016 Red Herring Top … | 6/14/2016

Biotheranostics to present feasibility data of gene expression profiling in blood

Biotheranostics, a leader in molecular diagnostics for cancer, announced results from a study developing a functional workflow for gene expression pro… | 4/22/2016

Celsee Diagnostics honored as one of the 2016 “Michigan 50 Companies to Watch”

Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, announced today that the company has been recognized as one of the 2016 “Mi… | 3/15/2016

With a new identity, liquid biopsy firm Celsee looks to move CTC isolation tech to clinic

NEW YORK (GenomeWeb) – Having recently changed its name and added new executives to its team, Plymouth, Michigan-based liquid biopsy firm Celsee Dia… | 2/16/2016

Celsee Diagnostics and collaborators publish validation study of automated CTC platform using clinical blood samples

Celsee Diagnostics, an innovator of cutting-edge products of liquid biopsy, announces the publication of “Development of an Automated and Sensitive … | 1/27/2016

Development of an automated and sensitive microfluidic device for capturing and characterizing circulating tumor cells (CTCs) from clinical blood samples

Abstract. Current analysis of circulating tumor cells (CTCs) is hindered by sub-optimal sensitivity and specificity of devices or assays as well as la… | 1/05/2016

 

CONTACT US ABOUT THE GENESIS SYSTEM

  • Systems
  • Applications
  • Support
  • News & Events
  • About Us
  • Contact Us
  • Newsletter Sign-up

© 2019 Celsee Inc., All Rights Reserved
Privacy Policy – Terms of Use
100 Phoenix Drive – Suite 321
Ann Arbor, MI 48108

Contact us today
866.748.1448
248.319.6919


LinkedInTwitterInstagram

Contact Us


To contact us regarding general inquiries, including questions, comments, and feedback, please fill out the form below:

Terms of Use | Privacy Policy | Email Preferences Center

Contact Tech Support


Celsee is committed to your success! Our technical support team strives to provide excellent customer support and to answer any of your questions. Complete the form below and we’ll reply in a timely manner.

Contact Sales


If you would like to have a Celsee representative contact you about pricing, products, or other information, please fill out the form below:

Terms of Use | Privacy Policy

The Latest Updates on Life Sciences Technology Delivered To Your Inbox

Terms of Use | Privacy Policy

Contact Us About the Genesis System
Submit an Application

For consideration, please fill the form out below. No phone calls, please. Only qualified candidates will be contacted.

First Name*

Last Name*

Email Address*

Phone Number*

Address Line 1*

Address Line 2

City*

State/Province/Territory*

Country*

Postal Code*

Are you authorized to work in the United States?*

Will you now or in the future require sponsorship for employment visa status?*

Were you referred by an existing employee?*

If yes, who referred you?

The position you're applying for: (prefilled)

Salary Requirements:*

Upload your resume: (.pdf and .doc file only) (recommended)

Upload your coverletter: (.pdf and .doc file only) (optional)

Would you like to include additional information about yourself? (optional)

*Celsee, Inc. is an equal opportunity employer, and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, protected veteran status or any other characteristic protected by law.

We use cookies in order to improve and customize your browsing experience. By continuing, you are consenting to our privacy policy. Accept Read More
Privacy Overview
Privacy Overview +

Privacy Overview